Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
New York, New York--(Newsfile Corp. - March 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) b
NEW YORK and NEW ORLEANS, March 27, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial
Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week
07:32pm, Friday, 27'th Mar 2026
It earned FDA approval for its cancer drug, Lifyorli. This earned a recommendation upgrade from an analyst.
SAN FRANCISCO, March 27, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline to move fo
New class action for Corcept (CORT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/21/2026.
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT).
Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives Average Recommendation of “Moderate Buy” from Analysts
05:36am, Friday, 27'th Mar 2026
Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, MarketBeat reports.
William Guyer Sells 11,767 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock
04:54am, Friday, 27'th Mar 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) insider William Guyer sold 11,767 shares of the business's stock in a transaction that occurred on Friday, March 20th. The shares wer
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit
11:04pm, Thursday, 26'th Mar 2026
NEW YORK, March 26, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between Octo
Lawsuit Alleges Management Concealed Repeated FDA Warnings Regarding Insufficient Data While Touting Pipeline Readiness; Firm Reminds Investors of April 21 Deadline SAN FRANCISCO, March 26, 2026 /PRNe
LOS ANGELES, March 26, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 21, 2026 deadline to file a lead plaintiff motion in the class action filed on
CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer
12:56pm, Thursday, 26'th Mar 2026
Corcept jumps after FDA approves Lifyorli combo for platinum-resistant ovarian cancer, marking the first-of-its-kind treatment.
Why Is Corcept (CORT) Up 11.7% Since Last Earnings Report?
12:32pm, Thursday, 26'th Mar 2026
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Suc
